Technical Analysis for GWPH - GW Pharmaceuticals Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical GWPH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Spinning Top | Other | -2.16% | |
| Upper Bollinger Band Walk | Strength | -2.16% | |
| Inside Day | Range Contraction | -2.16% | |
| Wide Bands | Range Expansion | -2.16% | |
| Overbought Stochastic | Strength | -2.16% | |
| Bearish Engulfing | Bearish | -2.96% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/11/2020
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
GW Pharmaceuticals plc, together with its subsidiaries, engages in the research, development, and commercialization of a range of cannabinoid prescription medicines. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in treatment of cancer pain. In addition, the company has two product candidates in Phase II trials in the field of diabetes and inflammation, as well as pre-clinical research programmes evaluating the use of selected cannabinoids for the treatment of glioma, epilepsy, and psychiatric illness. It has a strategic alliance with Otsuka Pharmaceutical Co. Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.
Health Cancer Pharmaceutical Industry Pain Drugs Diabetes Medication Treatment Of Cancer Inflammation Pharmaceuticals Policy Cannabis Epilepsy Glioma Cannabinoids Neuropathic Pain
Health Cancer Pharmaceutical Industry Pain Drugs Diabetes Medication Treatment Of Cancer Inflammation Pharmaceuticals Policy Cannabis Epilepsy Glioma Cannabinoids Neuropathic Pain
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 181.97 |
| 52 Week Low | 67.98 |
| Average Volume | 425,777 |
| 200-Day Moving Average | 113.49 |
| 50-Day Moving Average | 102.74 |
| 20-Day Moving Average | 116.03 |
| 10-Day Moving Average | 124.14 |
| Average True Range | 5.73 |
| ADX | 35.87 |
| +DI | 30.28 |
| -DI | 16.52 |
| Chandelier Exit (Long, 3 ATRs ) | 117.17 |
| Chandelier Exit (Short, 3 ATRs ) | 113.28 |
| Upper Bollinger Band | 134.14 |
| Lower Bollinger Band | 97.92 |
| Percent B (%b) | 0.69 |
| BandWidth | 31.22 |
| MACD Line | 6.67 |
| MACD Signal Line | 6.31 |
| MACD Histogram | 0.3582 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 127.28 | ||||
| Resistance 3 (R3) | 127.28 | 125.78 | 126.53 | ||
| Resistance 2 (R2) | 125.78 | 124.62 | 125.78 | 126.27 | |
| Resistance 1 (R1) | 124.26 | 123.91 | 123.51 | 124.26 | 126.02 |
| Pivot Point | 122.76 | 122.76 | 122.38 | 122.76 | 122.76 |
| Support 1 (S1) | 121.24 | 121.60 | 120.49 | 121.24 | 119.48 |
| Support 2 (S2) | 119.74 | 120.89 | 119.74 | 119.23 | |
| Support 3 (S3) | 118.22 | 119.74 | 118.98 | ||
| Support 4 (S4) | 118.22 |
